Approximately 5,000 people in the U.S. develop amyotrophic lateral sclerosis (ALS) each year. On average, they survive for only two to five years after being diagnosed, according to the Centers for ...

There are hardly any drugs against ALS. A new study shows that a substance acting on the MAPK signaling pathway may be effective against the neurodegenerative disease: After treatment with trametinib, ...

A study is exploring why athletes, first responders, and other high performers face an increased risk of developing ALS.

Amyotrophic lateral sclerosis, ALS for short, is a mysterious neurodegenerative disease that is almost always fatal. A consortium of researchers led by the Technical University of Munich (TUM) has ...

Approximately 5,000 people in the U.S. develop amyotrophic lateral sclerosis (ALS) each year. On average, they survive for only two to five years after being diagnosed, according to the Centers for ...

The study aims to enrol 12 adults with ALS at locations in Europe, the UK and US.

The pathway leading to the telltale sign of ALS, protein aggregation in the cytoplasm of motor neurons, has been revealed. Researchers from the University of California – San Diego (CA, USA) have ...

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder marked by progressive degeneration of upper and lower motor neurons, resulting in paralysis and death typically within 3-5 ...

Researchers identify a key pathway leading to neurodegeneration in early stages of ALS, hinting at the potential for short-circuiting the progression of the fatal disease if diagnosed early.